To further investigate the specific contribution of distinct oncogenes toward SCARNA15 regulation, we directly compared melanoma (MM383) and lung adenocarcinoma (A549) cells carrying BRAF and KRAS mutations, respectively, and lymphoma (Daudi) to breast (MDA-MB-436) cancer cells characterized by MYC gene alterations (Figure 1D). This evidence concerns the gene KRAS and lymphoma.